University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Phase II Study of Abraxane & Bevacizumab vs Ipilimumab for Stage IV Metastatic Malignant Melanoma
Official Title

Randomized Phase II Study of AB (Abraxane, Bevacizumab) versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative)

Description

Participants in this research study have Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative). Participants will receive either the drugs nab-paclitaxel( Abraxane®) and bevacizumab (Avastin®) or the commonly-used drug ipilimumab. The purpose of this study is to compare whether the study drugs nab-paclitaxel and bevacizumab keep cancer from getting worse for a longer period of time.

Approximately 16 people will take part in this study conducted by investigators at the University of Iowa. Up to 176 people will take part in this study at approximately 11 sites in the Midwest Melanoma Partnership group.

Start Date
April 14, 2014
End Date
December 1, 2015
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Melanie Frees      319-356-1228

Department
Hematology/Oncology
Keywords
Abraxane ; Bevacizumab ; Cancer ; Ipilimumab ; Melanoma ; Milhem ; Phase 2 ; Phase ii ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.